Evidence map›Paper›PMID 31371409›Full record

ArticleHaematologica2020

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment.

Barbara Depreter, Karin E Weening, Karl Vandepoele, Magnus Essand, Barbara De Moerloose, Maria Themeli, Jacqueline Cloos, Diana Hanekamp, Ine Moors, Inge D'hont and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Shared neoantigens for cancer immunotherapy.Molecular therapy. Oncology · 2025
    Review
  5. Nidogen-1, a Player in KMT2A-Rearranged Pediatric Acute Myeloid Leukemia.International journal of molecular sciences · 2025
    Article
  6. Article
  7. TARP as antigen in cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2021
    Review
  8. Review
  9. Review
  10. Oncoimmunology · 2021
    Article
  11. Clinical Significance ofHemaSphere · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 3 countries.

Barbara DepreterDepartment of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Karin E WeeningCancer Research Institute Ghent, Ghent University, Ghent, Belgium.
Karl VandepoeleCancer Research Institute Ghent, Ghent University, Ghent, Belgium.
Magnus EssandScience for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Barbara De MoerlooseDepartment of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Maria ThemeliDepartment of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
Jacqueline CloosDepartment of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
Diana HanekampDepartment of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
Ine MoorsDepartment of Hematology, Ghent University Hospital, Ghent, Belgium.
Inge D'hontDepartment of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium.
Barbara DenysCancer Research Institute Ghent, Ghent University, Ghent, Belgium.
Anne UyttebroeckDepartment of Pediatrics, University Hospital Gasthuisberg, Louvain, Belgium.
An Van DammeDepartment of Pediatric Hematology Oncology, University Hospital Saint-Luc, Brussels, Belgium.
Laurence DedekenDepartment of Pediatric Hematology Oncology, Queen Fabiola Children's University Hospital, Brussels, Belgium.
Sylvia SnauwaertDepartment of Hematology, AZ Sint-Jan Hospital Bruges, Bruges, Belgium.
Glenn GoetgelukDepartment of Diagnostic Sciences, Ghent University, Ghent, Belgium.
Stijn De MunterCancer Research Institute Ghent, Ghent University, Ghent, Belgium.
Tessa KerreCancer Research Institute Ghent, Ghent University, Ghent, Belgium.
Bart VandekerckhoveCancer Research Institute Ghent, Ghent University, Ghent, Belgium.
Tim LammensDepartment of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium tim.lammens@ugent.be.
Jan PhilippéCancer Research Institute Ghent, Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent · BEGhent University · BEAmsterdam UMC Location VUmc · NLGhent University Hospital · BEAZ Sint-Jan · BECliniques Universitaires Saint-Luc · BEQueen Fabiola Children's University Hospital · BEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapeutic strategies targeting the rare leukemic stem cell compartment might provide salvage to the high relapse rates currently observed in acute myeloid leukemia (AML). We applied gene expression profiling for comparison of leukemic blasts and leukemic stem cells with their normal counterparts. Here, we show that the T-cell receptor γ chain alternate reading frame protein (TARP) is over-expressed in

Indexed as

Leukemia, Myeloid, AcuteAdultChildHumansImmunotherapyMaleNuclear ProteinsReceptors, Antigen, T-CellNuclear ProteinsReceptors, Antigen, T-CellTARP

Identifiers

PMID31371409
PMCPMC7193481
OpenAlexW2966493469

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.